5 months Case for rivaroxaban and aspirin for pad gets stronger Philstar |Opinion
Combination treatment with aspirin and low dosage of the anticoagulant rivaroxaban has a broader benefit for reducing adverse events in patients with peripheral artery disease than initially reported from the COMPASS trial, which included more than 7,000 patients whose primary diagnosis at study entry was stable PAD. ... more